Patents by Inventor Thomas Francois Durand-Reville

Thomas Francois Durand-Reville has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for treating bacterial infections
    Patent number: 11046694
    Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: June 29, 2021
    Assignee: Entasis Therapeutics, Inc.
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang
  • Beta-lactamase inhibitor compounds
    Patent number: 10800778
    Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 13, 2020
    Assignee: Entasis Therapeutics Limited
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Lise Gauthier, John O'Donnell, Jan Romero, Ruben Tommasi, Jeroen Cunera Verheijen, Frank Wu, Xiaoyun Wu, Jing Zhang
  • COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
    Publication number: 20200165251
    Abstract: Provided herein are antibacterial compounds represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, Y, R4, R5, and R6 are as defined herein. Also provided are pharmaceutical compositions comprising the compounds of Formula I.
    Type: Application
    Filed: May 8, 2018
    Publication date: May 28, 2020
    Inventors: Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Satenig Guler, Jan Romero, Mark Sylvester, Ruben Tommasi, Camilo Velez-Vega, Xiaoyun Wu, Jing Zhang
  • Combination therapy for treatment of resistant bacterial infections
    Patent number: 10376499
    Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: August 13, 2019
    Assignee: Entasis Therapeutics Limited
    Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
  • BETA-LACTAMASE INHIBITOR COMPOUNDS
    Publication number: 20190202832
    Abstract: The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.
    Type: Application
    Filed: September 15, 2017
    Publication date: July 4, 2019
    Applicants: Entasis Therapeutics Limited, Entasis Therapeutics Limited
    Inventors: Gregory S. Basarab, Janelle Comita-Prevoir, Thomas Francois Durand-Reville, Lise Gauthier, Bill Moss, John O'Donnell, Jan Romero, Ruben Tommasi, Jeroen Cunera Verheijen, Frank Wu, Xiaoyun Wu, Jing Zhang
  • COMBINATION THERAPY FOR TREATMENT OF RESISTANT BACTERIAL INFECTIONS
    Publication number: 20180289681
    Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 9, 2018
    Publication date: October 11, 2018
    Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
  • Combination therapy for treatment of resistant bacterial infections
    Patent number: 9968593
    Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 15, 2018
    Assignee: Entasis Therapeutics Limited
    Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
  • COMBINATION THERAPY FOR TREATMENT OF RESISTANT BACTERIAL INFECTIONS
    Publication number: 20180000800
    Abstract: The present invention is directed to combinations of a ?-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of ?-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 17, 2015
    Publication date: January 4, 2018
    Inventors: Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
  • ?-lactamase inhibitor compounds
    Patent number: 9623014
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 18, 2017
    Assignee: Entasis Therapeutics Limited
    Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
  • BETA-LACTAMASE INHIBITOR COMPOUNDS
    Publication number: 20160175290
    Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 23, 2016
    Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler